Hopeful new approach for tough pancreatic cancer
NCT ID NCT03767582
Summary
This study tested whether adding two immunotherapy drugs (nivolumab and BMS-813160) with or without a cancer vaccine (GVAX) could help control locally advanced pancreatic cancer after standard chemotherapy and radiation. Researchers enrolled 46 patients to check if this combination was safe and if it boosted the immune system's attack on cancer cells. The goal was to see if this approach could help shrink tumors enough for surgery or extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.